低剂量纳尔特雷治疗耐火性癌症疼痛:初始安全性和有效性的病例系列
Aila Malik1, Alice Ye2, Matthew Chung2
1Department of Physical Medicine and Rehabilitation, University of Texas Health Science Center at Houston, Houston, United States.
Journal of pain and symptom management
|August 23, 2025
概括
低剂量纳尔特雷 (LDN) 对治疗耐火性癌症疼痛具有前景,在早期随访中表现出良好的耐受性和较低的不良事件发生率. 这项研究表明LDN可能是癌症患者经历持续疼痛的有益选择.
科学领域:
- 癌症学
- 治疗疼痛
- 药理学
背景情况:
- 低剂量纳尔特 (LDN) 是用于非癌症慢性疼痛的非标签药物.
- 它在与癌症相关的疼痛中的有效性尚未得到充分证实.
研究的目的:
- 评估LDN治疗耐火性癌症疼痛的安全性和有效性.
- 评估从启动到两次后续访问的LDN结果.
主要方法:
- 在癌症患者处方LDN (2022-2023) 的回顾性图表.
- 患者根据自身报告的疼痛改善而被归类为响应者.
- 收集有关癌症诊断,疼痛类型,LDN剂量,反应率和不良事件的数据.
主要成果:
- 20名癌症患者接受了LDN; 45%的患者患有乳腺癌.
- 在第一次和第二次随访中,阳性反应率分别为80%和76. 9%.
- 与治疗相关的神经病变显示了71%的反应率;轻微的不良事件很少发生,并且可以控制.
结论:
- 在耐火性癌症疼痛方面,LDN似乎具有潜在的益处.
- 在这组患者中,LDN耐受性良好,不良事件发生率低.
- 需要对癌症疼痛管理的LDN进行进一步的研究.
相关概念视频
Analgesia and Pain Management
788
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
788
Opioid Analgesics: Synthetic and Semisynthetic Opioids
426
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
426
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
366
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
366
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


